Sinocare(SZ:300298) 光大证券研究·2025-10-27 23:04Core Viewpoint - The company reported a strong revenue growth in Q3 2025, but net profit declined significantly due to a one-time patent payment, indicating underlying business strength when excluding this impact [4][5]. Financial Performance - For the first three quarters of 2025, the company achieved a revenue of 3.453 billion yuan, a year-on-year increase of 8.52%, while net profit attributable to shareholders was 211 million yuan, down 17.36% [4]. - In Q3 2025, the company recorded a revenue of 1.190 billion yuan, reflecting a year-on-year growth of 13.40%, but net profit dropped by 47.55% to 30 million yuan due to a one-time payment of 19 million USD (approximately 136 million yuan) related to a patent settlement [4][5]. Business Segments - The Continuous Glucose Monitoring (CGM) business has become a key driver of growth, with the company on track to meet its annual sales targets. A differentiated strategy is employed, focusing on cost-effective first-generation products and high-end second-generation products [6]. - The domestic BGM business continues to show steady growth, while the overseas market is seeing positive developments, particularly in Europe and the Middle East, where CGM products are gaining insurance coverage [6]. Market Challenges - The company faces short-term uncertainties due to a patent lawsuit initiated by Abbott in Europe, which affects the sales of the first-generation CGM products in certain countries. However, the second-generation products are not impacted, and the company is actively evaluating promotional strategies for these products in Europe [7]. - The overseas subsidiaries, particularly Trividia, are showing continuous revenue growth, and there is a noticeable improvement in the operations of PTS. The company has established a global sales network and brand resources, indicating potential for successful international expansion [8].